Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Opnurasib · JDQ-443

Small molecule · Inhibitor of KRAS G12C mutant (KRAS) · developed by Novartis Pharmaceuticals

Phase 3 Most advanced trial (none active)
NVS Developer

What is Opnurasib?

Opnurasib (JDQ443) is an oral small molecule that selectively targets the KRAS G12C mutant protein and inhibits its signaling, which drives tumor cell growth and proliferation. It is studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
JDQ-443
Drug type
Small molecule
Targets
KRAS G12C mutant (KRAS)
Mechanism
Inhibitor of KRAS G12C mutant (KRAS)
Pathways
KRAS G12C mutant-dependent signaling
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
Q3W0H3V1LQ

Conditions studied

Non-Small Cell Lung Cancer

Other drugs acting on KRAS

More from Novartis Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Opnurasib

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.